Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-05-15 4:32 pm Purchase |
2025-03-31 | 13G | CG Oncology, Inc. Common stock CGON |
TCG Crossover GP I, LLC | 3,670,206 4.800% |
100,000 (+2.80%) |
Filing History |
| 2025-02-14 5:40 pm Purchase |
2024-12-31 | 13G | CG Oncology, Inc. Common stock CGON |
Decheng Capital Global Life Sciences Fund IV, L.P. | 6,371,669 8.400% |
912,859 (+16.72%) |
Filing History |
| 2025-01-28 5:08 pm Sale |
2024-12-31 | 13G | CG Oncology, Inc. Common stock CGON |
Unique Diamond Investments Limited | 4,211,341 5.500% |
-1,343,955 (-24.19%) |
Filing History |
| 2024-11-12 2:30 pm Unchanged |
2024-09-30 | 13G | CG Oncology, Inc. Common stock CGON |
The Vanguard Group | 5,081,352 7.570% |
0 (Unchanged) |
Filing History |
| 2024-11-08 2:17 pm Unchanged |
2024-09-30 | 13G | CG Oncology, Inc. Common stock CGON |
BlackRock Inc. BLK |
3,570,927 5.300% |
0 (Unchanged) |
Filing History |
| 2024-11-04 10:22 am Purchase |
2024-09-30 | 13G | CG Oncology, Inc. Common stock CGON |
The Vanguard Group | 5,081,352 7.570% |
5,081,352 (New Position) |
Filing History |
| 2024-10-22 6:06 pm Purchase |
2024-09-30 | 13G | CG Oncology, Inc. Common stock CGON |
BlackRock Inc. BLK |
3,570,927 5.300% |
3,570,927 (New Position) |
Filing History |
| 2024-07-22 4:35 pm Purchase |
2024-06-30 | 13G | CG Oncology, Inc. Common stock CGON |
Unique Diamond Investments Limited | 5,555,296 8.300% |
5,555,296 (New Position) |
Filing History |
| 2024-04-09 7:12 pm Purchase |
2024-01-29 | 13G | CG Oncology, Inc. Common stock CGON |
Decheng Capital Global Life Sciences Fund IV, L.P. | 5,458,810 8.200% |
400,000 (+7.91%) |
Filing History |
| 2024-03-14 7:25 pm Purchase |
2024-01-29 | 13G | CG Oncology, Inc. Common stock CGON |
Kissei Pharmaceutical Co. Ltd. | 3,543,533 5.300% |
3,543,533 (New Position) |
Filing History |
| 2024-02-09 4:31 pm Purchase |
2024-01-29 | 13G | CG Oncology, Inc. Common stock CGON |
TCG Crossover GP I, LLC | 3,570,206 5.400% |
3,570,206 (New Position) |
Filing History |
| 2024-02-08 5:17 pm Purchase |
2024-01-29 | 13G | CG Oncology, Inc. Common stock CGON |
Decheng Capital Global Life Sciences Fund IV, L.P. | 5,058,810 7.600% |
5,058,810 (New Position) |
Filing History |
| 2024-02-05 4:40 pm Purchase |
2024-01-29 | 13G | CG Oncology, Inc. Common stock CGON |
Longitude Capital Partners IV LLC | 4,662,281 7.000% |
4,662,281 (New Position) |
Filing History |
| 2024-02-05 3:15 pm Purchase |
2024-01-24 | 13G | CG Oncology, Inc. Common stock CGON |
Foresite Capital Fund V L.P. | 3,595,203 5.700% |
3,595,203 (New Position) |
Filing History |